Advances in the Role of NLRP3 Inflammasome in Cardiovascular Diseases

Cheng Caocao; Tan Juanjuan; Ju Jiaxin; Kang Yalong; Wang Haifang

doi:10.23977/medbm.2024.020103

Advances in the Role of NLRP3 Inflammasome in Cardiovascular Diseases

Download as PDF

DOI: 10.23977/medbm.2024.020103 | Downloads: 24 | Views: 282

Author(s)

Cheng Caocao ¹, Tan Juanjuan ¹, Ju Jiaxin ¹, Kang Yalong ¹, Wang Haifang ¹

Affiliation(s)

¹ Shaanxi University of Chinese Medicine, Xianyang, Shaanxi, 712046, China

Corresponding Author

Wang Haifang

ABSTRACT

The NLRP3 inflammasome is a critical multiprotein signaling platform that activates caspase-1, leading to the maturation of pro-inflammatory cytokines interleukin-1β (IL-1β) and IL-18, and triggering inflammatory responses. Inflammation has been implicated as a significant process in cardiovascular diseases. The activation of the NLRP3 inflammasome is associated with the pathogenesis of cardiovascular diseases, including hypertension, atherosclerosis, and heart failure. This article provides an overview of the role, mechanisms, and potential therapeutic interventions related to the activation of the NLRP3 inflammasome in the occurrence and development of cardiovascular-related diseases.

KEYWORDS

NLPR3 inflammatory body; proinflammatory cytokines; inflammatory reaction; hypertension; atherosclerosis; heart failure; Cardiovascular disease

CITE THIS PAPER

Cheng Caocao, Tan Juanjuan, Ju Jiaxin, Kang Yalong, Wang Haifang, Advances in the Role of NLRP3 Inflammasome in Cardiovascular Diseases. MEDS Basic Medicine (2024) Vol. 2: 15-23. DOI: http://dx.doi.org/10.23977/medbm.2024.020103.

REFERENCES

[1] Salim Yusuf, Philip Joseph, Sumathy Rangarajan, et al. Modifiable risk factors, cardiovascular disease, and mortality in 155 722 individuals from 21 high-income, middle-income, and low-income countries (PURE): a prospective cohort study [J]. The Lancet, 2020, 395(10226):795-808.
[2] Ridker Paul M, Everett Brendan M, Thuren Tom, et al. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease [J]. The New England journal of medicine, 2017, 377(12):1119-1131.
[3] Miao Liu, Huang Zhenqi, Chen Ningyuan. Research advances in targeted therapy for heart failure [J]. Chinese Journal of Atherosclerosis, 2023, 31(06): 517-526.
[4] Que Xiangyong, Zheng Sihao, Song Qibin, et al. Fantastic voyage: The journey of NLRP3 inflammasome activation [J]. Genes & Diseases, 2024, 11(2):819-829.
[5] Sharif Humayun, Wang Li, Wang Weili, et al. Structural mechanism for NEK7-licensed activation of NLRP3 inflammasome [J]. Nature, 2019, 570(7761):338-343.
[6] Laurence Feldmeyer, Martin Keller, Gisela Niklaus, et al. The Inflammasome Mediates UVB-Induced Activation and Secretion of Interleukin-1β by Keratinocytes [J]. Current Biology, 2007, 17(13):1140-1145.
[7] Katsnelson Michael A, Rucker L Graham, Russo Hana M, et al. K+ efflux agonists induce NLRP3 inflammasome activation independently of Ca2+ signaling [J]. Journal of immunology (Baltimore, Md.: 1950), 2015, 194(8):3937-3952.
[8] Katsnelson Michael A, Lozada-Soto Kristen M, Russo Hana M, et al. NLRP3 inflammasome signaling is activated by low-level lysosome disruption but inhibited by extensive lysosome disruption: roles for K+ efflux and Ca2+ influx [J]. American journal of physiology. Cell physiology, 2016, 311(1):C83-C100.
[9] Luzardo Leonella, Noboa Oscar, Boggia José, et al. Mechanisms of Salt-Sensitive Hypertension [J]. Current hypertension reviews, 2015, 11(1):14-21.
[10] Fujita Toshiro. Mechanism of salt-sensitive hypertension: focus on adrenal and sympathetic nervous systems [J]. Journal of the American Society of Nephrology: JASN, 2014, 25(6):1148-1155.
[11] Wenqiang Gan, Jingyuan Ren, Tiegang Li, et al. The SGK1 inhibitor EMD638683, prevents Angiotensin II–induced cardiac inflammation and fibrosis by blocking NLRP3 inflammasome activation [J]. BBA - Molecular Basis of Disease, 2018, 1864(1):1-10.
[12] Yang Bin, Chen Zhe, Quan Honghan, et al. The protective effect of hesperidin on cardiac and renal tissue damage in DOCA/Salt hypertensive rats [J]. Chinese Pharmacological Bulletin, 2023, 39(09): 1705-1710.
[13] Wu Jie, Ma Hong, Zhao Guangbin. Role of NLRP3 Inflammasome in Hypertension Pathogenesis [J]. Chinese Community Doctors, 2022, 38(23):7-9.
[14] Wei Chen, Nikolaos G. Frangogiannis. Fibroblasts in post-infarction inflammation and cardiac repair [J]. BBA - Molecular Cell Research, 2013, 1833(4):945-953.
[15] Guo Bing, He Xuan, Yu Yi, et al. Effects of Xinkang Chongzhi on cardiomyocyte pyroptosis in rats with chronic heart failure[J/OL]. Chinese Journal of Traditional Chinese Medicine: 1-15[2024-01-05].
[16] Lu Aimin, Zhao Yan, Tong Youfu. Regulating effect of salvianolic acid on neuroimmunity in rats with acute heart failure [J]. Biotechnology, 2021, 31(05):478-482.
[17] Huang Guowei, Yu You, Zhang Huan, et al. Study on Mechanism of Yuxuebi Capsule-Containing Serum Regulating NLRP3-Mediated Pyroptosis on Myocardial Cell [J]. Chinese Journal of Traditional Chinese Medicine, 2022, 40(5):130-133.
[18] Duewell Peter, Kono Hajime, Rayner Katey J, et al. NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals [J]. Nature, 2010, 464(7293):1357-1361.
[19] Zeng Zhaolin, Chen Jiaojiao, Wu Peng, et al. OxLDL induces vascular endothelial cell pyroptosis through miR-125a-5p/TET2 pathway [J]. Journal of cellular physiology, 2019, 234(5):7475-7491.
[20] Jiang Chunteng, Xie Santuan, Yang Guang, et al. Spotlight on NLRP3 Inflammasome: Role in Pathogenesis and Therapies of Atherosclerosis [J]. Journal of inflammation research, 2021, 14:7143-7172.
[21] Zeng Xiangfa, Wang Wusheng, Cheng Xuan, et al. Regulation of intestinal flora and inhibition of lipopolysaccharide-mediated inflammatory pathway by resolving phlegm, activating blood circulation and promoting collaterals formula improves vascular injury in atherosclerotic mice [J/OL]. Chinese Journal of Traditional Chinese Medicine: 1-12[2024-01-05].
[22] Ge Fan, Wang Wenkai, Zhu Jingtian, et al. AstragalosideⅣRegulates Blood Lipid and Inflammatory Factors Through NLPR3 Inflammasome in Early Diabetic Atherosclerosis Rats [J]. Journal of Nanjing University of Traditional Chinese Medicine, 2021, 37(03): 383- 387.
[23] Zhang Lixia, Ai Chenchen, Bai Ming, et al. NLRP3 Inflammasome/Pyroptosis: A Key Driving Force in Diabetic Cardiomyopathy [J]. International Journal of Molecular Sciences, 2022, 23(18):10632-10632.
[24] Wang Yueqiu, Li Hui, Li Yang, et al. Coriolus versicolor alleviates diabetic cardiomyopathy by inhibiting cardiac fibrosis and NLRP3 inflammasome activation [J]. Phytotherapy research: PTR, 2019, 33(10):2737-2748.
[25] Li Xuelian, Li Zhiyang, Li Bingong, et al. Quercetin inhibits inflammasome activation in diabetic rats and attenuates myocardial injury [J]. Chinese Journal of Pathophysiology, 2019, 35(8):1345-1351.
[26] Yang Zhangliang, Xu Huilin, Cheng Yin, et al. Effect of ursolic acid on cardiomyopathy of mice with diabetes and its mechanism [J]. Chinese journal of applied physiology, 2018, 34(4):309-312+339.
[27] Luan Fei, Rao Zhili, Peng Lixia, el al. Cinnamic acid preservesagainst myocardial ischemia/reperfusion injury via suppressionof NLRP3/Caspase-1/CSDMD signaling pathway [J]. Phytomedicine: international journal of phytotherapy and phytopharmacology, 2022, 100:154047.
[28] Xiao Min, Xiang Jingjing, Wang Wei, et al. Jinxiangdan Inhibits NLRP3/IL-1β/Caspase-1 Pathway to Alleviate Myocardial Ischemia-reperfusion Injury in Rats [J]. Chinese Journal of Experimental Traditional Medical Formulae, 2021, 27(20): 87-94.
[29] Wang Chen, Wang Yahong, Song Dandan, et al. Therapeutic Effects of Modified Si-Miao-Yong-An Decoction in the Treatment of Rat Myocardial Ischemia/Reperfusion Injury [J]. Evidence-based complementary and alternative medicine : eCAM, 2022, 2022:1442405-1442405.
[30] Wang Danshu, Yan Liuyan, Sun Shuchan, et al. Puerarin protects against myocardial ischemia/reperfusion injury by suppressing NLRP3 inflammasome activation via TLR4/Myd88/NF-κB pathway in rats [J]. Acta Pharmaceutica Sinica, 2021, 56(5): 1343-1351.
[31] Li Xueling, Zhu Qin, Wang Qingcheng, et al. Protection of Sacubitril/Valsartan against Pathological Cardiac Remodeling by Inhibiting the NLRP3 Inflammasome after Relief of Pressure Overload in Mice [J]. Cardiovascular drugs and therapy, 2020, 34(5):1-12.
[32] Tan Yu, Chai Hua, Ma Xiaojuan. Effect of Lingbao Huxin Pill on NLRP3/Caspase-1 Pyroptosis Pathway in Myocardium of Actue Myocardial Infarction Rats [J]. Chinese Journal of Integrated Traditional and Western Medicine, 2023, 43(01):90-96.
[33] Zhao Shuai. Study on the role and mechanism of expectorant and stasis-removing traditional Chinese medicine compound in atrial fibrillation by inhibiting small activation of NLRP3 inflammation [D]. Liaoning University of Traditional Chinese Medicine, 2023.
[34] Zhang Xiaolei, Zhang Kai, Qin Yongting, et al. Protective effect of luteolin on viral myocarditis by regulating AMPK/NLRP3 axis-mediated pyroptosis [J]. Journal of Pathogen Biology, 2022, 17(05):514-519.
[35] Kobayashi Motoi, Usui-Kawanishi Fumitake, Karasawa Tadayoshi, et al. The cardiac glycoside ouabain activates NLRP3 inflammasomes and promotes cardiac inflammation and dysfunction [J]. PloS one, 2017, 12(5):e0176676.
[36] Wu Danbin, Chen Yefei, Sun Yingxin, et al. Target of MCC950 in Inhibition of NLRP3 Inflammasome Activation: a Literature Review [J]. Inflammation, 2020, 43(1):17-23.
[37] Koichiro Fujisue, Koichi Sugamura, Hirofumi Kurokawa, et al. Colchicine Improves Survival, Left Ventricular Remodeling, and Chronic Cardiac Function After Acute Myocardial Infarction [J]. Circulation Journal, 2017, 81(8): 1174-1182.
[38] Marchetti Carlo, Toldo Stefano, Chojnacki Jeremy, et al. Pharmacologic Inhibition of the NLRP3 Inflammasome Preserves Cardiac Function After Ischemic and Nonischemic Injury in the Mouse [J]. Journal of cardiovascular pharmacology, 2015, 66(1):1-8.

Subscription

E-Mail Alert

Downloads:	385
Visits:	13049

Advances in the Role of NLRP3 Inflammasome in Cardiovascular Diseases

Author(s)

Affiliation(s)

Corresponding Author

ABSTRACT

KEYWORDS

CITE THIS PAPER

REFERENCES

RESOURCES

JOIN US

PUBLICATION SERVICES

CONTACT US